BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

936 related articles for article (PubMed ID: 22426346)

  • 1. EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy.
    Koh A; Lee WK; Chen LJ; Chen SJ; Hashad Y; Kim H; Lai TY; Pilz S; Ruamviboonsuk P; Tokaji E; Weisberger A; Lim TH
    Retina; 2012 Sep; 32(8):1453-64. PubMed ID: 22426346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: A Randomized Clinical Trial.
    Koh A; Lai TYY; Takahashi K; Wong TY; Chen LJ; Ruamviboonsuk P; Tan CS; Feller C; Margaron P; Lim TH; Lee WK;
    JAMA Ophthalmol; 2017 Nov; 135(11):1206-1213. PubMed ID: 28983556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: The EVEREST II Randomized Clinical Trial.
    Lim TH; Lai TYY; Takahashi K; Wong TY; Chen LJ; Ruamviboonsuk P; Tan CS; Lee WK; Cheung CMG; Ngah NF; Patalauskaite R; Margaron P; Koh A;
    JAMA Ophthalmol; 2020 Sep; 138(9):935-942. PubMed ID: 32672800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month MONT BLANC study results.
    Larsen M; Schmidt-Erfurth U; Lanzetta P; Wolf S; Simader C; Tokaji E; Pilz S; Weisberger A;
    Ophthalmology; 2012 May; 119(5):992-1000. PubMed ID: 22424834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravitreal ranibizumab with or without photodynamic therapy for the treatment of symptomatic polypoidal choroidal vasculopathy.
    Lai TY; Lee GK; Luk FO; Lam DS
    Retina; 2011 Sep; 31(8):1581-8. PubMed ID: 21610566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month results of the DENALI study.
    Kaiser PK; Boyer DS; Cruess AF; Slakter JS; Pilz S; Weisberger A;
    Ophthalmology; 2012 May; 119(5):1001-10. PubMed ID: 22444829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the effect of ranibizumab and verteporfin for polypoidal choroidal vasculopathy: 12-month LAPTOP study results.
    Oishi A; Kojima H; Mandai M; Honda S; Matsuoka T; Oh H; Kita M; Nagai T; Fujihara M; Bessho N; Uenishi M; Kurimoto Y; Negi A
    Am J Ophthalmol; 2013 Oct; 156(4):644-51. PubMed ID: 23876867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravitreal ranibizumab combined with verteporfin photodynamic therapy for treating polypoidal choroidal vasculopathy.
    Lee YH; Lee EK; Shin KS; Lee KM; Kim JY
    Retina; 2011; 31(7):1287-93. PubMed ID: 21386762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LAPTOP study: a 24-month trial of verteporfin versus ranibizumab for polypoidal choroidal vasculopathy.
    Oishi A; Miyamoto N; Mandai M; Honda S; Matsuoka T; Oh H; Kita M; Nagai T; Bessho N; Uenishi M; Kurimoto Y; Negi A
    Ophthalmology; 2014 May; 121(5):1151-2. PubMed ID: 24484991
    [No Abstract]   [Full Text] [Related]  

  • 10. Polypoidal choroidal vasculopathy: evidence-based guidelines for clinical diagnosis and treatment.
    Koh AH; ; Chen LJ; Chen SJ; Chen Y; Giridhar A; Iida T; Kim H; Yuk Yau Lai T; Lee WK; Li X; Han Lim T; Ruamviboonsuk P; Sharma T; Tang S; Yuzawa M
    Retina; 2013 Apr; 33(4):686-716. PubMed ID: 23455233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparisons of outcomes with different intervals between adjunctive ranibizumab and photodynamic therapy for polypoidal choroidal vasculopathy.
    Sato T; Kishi S; Matsumoto H; Mukai R
    Am J Ophthalmol; 2013 Jul; 156(1):95-105.e1. PubMed ID: 23628354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 1-year results of combined half-dose photodynamic therapy and ranibizumab for polypoidal choroidal vasculopathy.
    Wong IY; Shi X; Gangwani R; Zhao P; Iu LP; Li Q; Ng A; Li X
    BMC Ophthalmol; 2015 Jun; 15():66. PubMed ID: 26122636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined reduced fluence photodynamic therapy and intravitreal ranibizumab for polypoidal choroidal vasculopathy.
    Ricci F; Calabrese A; Regine F; Missiroli F; Ciardella AP
    Retina; 2012 Jul; 32(7):1280-8. PubMed ID: 22218148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined intravitreal ranibizumab and photodynamic therapy for polypoidal choroidal vasculopathy.
    Saito M; Iida T; Kano M
    Retina; 2012 Jul; 32(7):1272-9. PubMed ID: 22547209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of combined photodynamic therapy and intravitreal bevacizumab injection versus photodynamic therapy alone in polypoidal choroidal vasculopathy.
    Kim SJ; Yu HG
    Retina; 2011 Oct; 31(9):1827-34. PubMed ID: 21734621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subfoveal retinal and choroidal thickness after verteporfin photodynamic therapy for polypoidal choroidal vasculopathy.
    Maruko I; Iida T; Sugano Y; Saito M; Sekiryu T
    Am J Ophthalmol; 2011 Apr; 151(4):594-603.e1. PubMed ID: 21295766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. INITIAL VERSUS DELAYED PHOTODYNAMIC THERAPY IN COMBINATION WITH RANIBIZUMAB FOR TREATMENT OF POLYPOIDAL CHOROIDAL VASCULOPATHY: The Fujisan Study.
    Gomi F; Oshima Y; Mori R; Kano M; Saito M; Yamashita A; Iwata E; Maruko R;
    Retina; 2015 Aug; 35(8):1569-76. PubMed ID: 25830698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the effects of photodynamic therapy, intravitreal ranibizumab and combination for polypoidal choroidal vasculopathy under 1 + PRN regimen.
    Lai K; Li Y; Zhou L; Zhong X; Huang C; Xu F; Lu L; Ge J; Jin C
    BMC Ophthalmol; 2018 Jun; 18(1):144. PubMed ID: 29925341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Photodynamic therapy, ranibizumab, and ranibizumab with photodynamic therapy for the treatment of polypoidal choroidal vasculopathy.
    Rouvas AA; Papakostas TD; Ntouraki A; Douvali M; Vergados I; Ladas ID
    Retina; 2011 Mar; 31(3):464-74. PubMed ID: 20948458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two-year results of combined intravitreal ranibizumab and photodynamic therapy for polypoidal choroidal vasculopathy.
    Saito M; Iida T; Kano M; Itagaki K
    Graefes Arch Clin Exp Ophthalmol; 2013 Sep; 251(9):2099-110. PubMed ID: 23553286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.